Power Grid

Showing 4072 articles
Business

Merck Navigates Mixed Q4 2025 with Oncology Strength Offsetting Vaccine Slump, Sets Cautious 2026 Outlook

Merck & Co. reported a 5% rise in Q4 2025 revenue to $16.4 billion, powered by its blockbuster cancer drug Keytruda and animal health division. However, a steep 35% drop in Gardasil sales, attributed to weakened demand in Asia, highlighted regional vulnerabilities. The pharmaceutical giant issued initial 2026 guidance projecting modest growth while absorbing a significant one-time charge from its recent Cidara Therapeutics acquisition.

Business

Microsoft's Maia 200 AI Chip and Expanding Partnerships Signal Strategic Pivot, Testing Investor Confidence

Microsoft unveils its second-generation Maia 200 AI accelerator, deepening hardware independence while expanding AI collaborations with Itron, Richtech Robotics, and Perplexity. As the tech giant's cloud backlog swells—with a significant portion tied to OpenAI—investors are weighing the capital intensity and concentration risks of its all-in AI infrastructure bet against its long-term growth narrative.